1/31/2022 | IGLM | Shire Acquisitions to redeem $1.5 billion 2.875% notes due 2023
|
10/8/2021 | BK | Takeda to repay $1.7 billion term loan due 2025
|
12/21/2020 | IGLM | Shire Acquisitions to redeem $900 million 2.4% notes due 2021
|
1/8/2019 | IG | S&P lowers Takeda
|
9/10/2018 | IGLM | Shire and units price tender offer, increase cap to $2.33 billion
|
9/10/2018 | IGLM | Shire, units post early results of month-long capped tender offer
|
8/24/2018 | IGLM | Shire, units hold month-long tender for $2.25 billion of five series
|
5/9/2018 | BKIG | Moody’s reviews Shire, Baxalta
|
5/9/2018 | BKIG | S&P reviews Shire, Takeda
|
3/20/2018 | BKIG | Moody’s revises Shire to positive
|
7/26/2017 | SP | New Issue: Barclays prices $5.24 million contingent income autocallables on Shire
|
7/17/2017 | SP | Barclays to price 8% contingent income autocallables linked to Shire
|
12/2/2016 | BK | Shire extends $2.1 billion revolver by one year to December 2021
|
9/29/2016 | IG | Market Commentary: Fortis, Viacom, DTE Energy price bonds; credit spreads widen; HSBC tightens; Shire softens
|
9/29/2016 | IG | Market Commentary: Morning Commentary: Viacom, DTE, Fortis to price; HSBC tightens; Shire softens; CDX eases
|
9/26/2016 | IG | Market Commentary: Kroger, AvalonBay, Air Lease, Southwest Gas price; Hercules markets; credit spreads widen
|
9/26/2016 | IG | Market Commentary: Morning Commentary: High-grade deal pipeline active; Shire firms; credit spreads mostly flat
|
9/23/2016 | IG | Market Commentary: Flowers Foods, Fannie Mae price; Air Liquide tightens; Shire flat to softer; Goldman firms
|
9/23/2016 | IG | Market Commentary: Morning Commentary: Flowers Foods in deal pipeline; Shire notes flat; credit spreads steady
|
9/22/2016 | IG | Market Commentary: High-grade primary action resumes; Fannie Mae to price; Microsoft eases; Shire mostly flat
|
9/22/2016 | IG | Market Commentary: Morning Commentary: First Midwest Bancorp preps issue; credit spreads firm; Shire mostly flat
|
9/21/2016 | IG | Market Commentary: High-grade primary quiet; deal action forecast; Verizon tightens; Google eases; Shire mixed
|
9/21/2016 | IG | Market Commentary: Morning Commentary: High-grade primary action thins; Shire bonds mixed in secondary trading
|
9/20/2016 | IG | New Issue: Shire details $12.1 billion sale of notes in four tranches
|
9/19/2016 | IG | Market Commentary: Shire prices $12.1 billion; Hess, American Airlines, S&P tap market; credit spreads firm
|
9/19/2016 | IG | New Issue: Shire Acquisitions Investments Ireland prices $12.1 billion notes in four tranches
|
9/16/2016 | BKIG | Moody’s rates Shire notes Baa3
|
9/16/2016 | BKIG | S&P applies BBB- to Shire notes
|
9/8/2016 | IG | Market Commentary: Toronto-Dominion, GATX, Bemis price; Shire preps five-part deal; credit spreads flat
|
9/8/2016 | IG | Shire Acquisitions Investments Ireland offers notes in five tranches
|
6/3/2016 | BK | Shire draws $12.39 billion of bridge loan to finance Baxalta purchase
|
6/3/2016 | BK | Baxalta terminates five-year credit facility upon merging with Shire
|
1/28/2016 | BKIG | Moody’s assigns Baa3 to Shire
|
1/11/2016 | BKIG | Shire gets $18 billion bridge facility for combination with Baxalta
|
11/30/2015 | BK | Shire extends $2.1 billion revolving credit facilities to Dec. 12, 2020
|
11/2/2015 | BK | Shire secures $5.6 billion term loan facility for Dyax acquisition
|
1/12/2015 | BKBWHY | Shire arranges $850 million short-term bank facility with Citibank to fund NPS Pharma acquisition
|
12/17/2014 | BK | Shire enters into $2.1 million five-year revolving credit facility
|
7/18/2014 | BKIG | AbbVie secures £13.5 billion bridge facility to fund merger with Shire
|
4/11/2014 | BK | Shire reduces term loan to $350 million from $550 million
|
2/21/2014 | BK | Shire cancels $350 million of term loan with no convertibles to redeem
|
12/16/2013 | CVLM | Shire to redeem remaining 2.75% bonds; 99.91% already converted
|
12/16/2013 | BK | Shire, Morgan Stanley agree to cancel $850 million of $1.75 billion term
|
11/26/2013 | CVLM | Shire exercises redemption right on $1.08 billion of 2.75% convertibles
|
11/12/2013 | BK | Shire enters into $2.6 billion facilities agreement via Morgan Stanley
|
5/9/2012 | CVLM | Shire holders do not exercise put on $1.1 billion 2.75% convertibles
|
2/23/2012 | CVLM | Shire: Holders unlikely to put $1.1 billion 2.75% convertibles in May
|
7/25/2007 | BK | Shire amends loan, increasing revolver size, revising covenants
|
5/8/2007 | CV | Shire greenshoe fully exercised, lifts 2.75% convertibles to $1.1 billion
|
5/2/2007 | BK | Shire to repay some bank debt with convertibles proceeds
|
5/2/2007 | CV | New Issue: Shire prices $1 billion seven-year convertibles within talk to yield 2.75%, up 45%
|
4/20/2007 | SS | Shire completes acquisition of New River
|
4/18/2007 | SS | Shire completes tender offer for New River shares
|
4/16/2007 | SS | Shire shareholders vote to approve New River tender offer, increase borrowings
|
2/20/2007 | PP | Market Commentary: Shire wraps £461 million stock sale for acquisition; Bayou Bend seals C$200 million offering
|
2/20/2007 | PP | New Issue: Shire sells £461 million of shares as part of acquisition
|
2/20/2007 | SS | Market Commentary: XM, Sirius up; EMI, Warner up; Vulcan lifts Rinker; Shire, New River rise; Tessco up, Sirva up
|
2/20/2007 | SS | Shire to acquire New River Pharmaceuticals for $64 per share
|
11/9/2006 | BT | Bear starts Shire with $67 target
|
11/3/2006 | BT | Shire remains at hold for Jefferies
|
10/30/2006 | BT | Shire at sector perform by RBC
|
10/27/2006 | BT | Shire reports 19% third-quarter revenue growth over 2005; cash at $984.8 million
|
10/11/2006 | BT | Shire gets sector perform rating by RBC
|
10/9/2006 | BT | Shire on hold by Jefferies
|
10/9/2006 | BT | Market Commentary: New River rises 61.5%, Shire up 16% on ADHD drug nod; Coley eyed; NeoPharm higher by 20%
|
9/8/2006 | BT | Shire: FDA extends review period for Mesavance
|
8/30/2006 | BT | Market Commentary: AnorMED snubs Genzyme bid; PDL higher as Roche backs out; Vasogen zooms 42%; Adeza up
|
8/29/2006 | BT | Jefferies updates specialty pharmaceutical market
|
8/24/2006 | BT | Market Commentary: Biovail sues U.S. FDA; Dendreon's stock climbs after seeking application from FDA
|
8/24/2006 | BT | Shire files NDA for attention-deficit drug guanfacine
|
8/16/2006 | BT | Shire reiterated at sector perform by RBC
|
8/16/2006 | BT | Shire on hold by Jefferies
|
8/15/2006 | BT | Barr and its Duramed subsidiary settle Adderall litigation with Shire, sign additional agreements
|
8/15/2006 | BT | Jefferies puts Shire on hold
|
8/15/2006 | BT | Market Commentary: Acadia gains; Shire, Barr, New River up on settlement; Novavax rises; Vasogen off
|
8/11/2006 | BT | Shire on hold by Jefferies
|
7/31/2006 | BT | Shire at sector perform by RBC
|
7/28/2006 | BT | Shire on hold by Jefferies
|
7/28/2006 | BT | Shire revenues up for the second quarter at $439.1 million
|
7/25/2006 | BT | Shire on hold by Merrill
|
7/24/2006 | BT | Shire gets FDA approval to sell Elaprase for Hunter syndrome
|
7/21/2006 | BT | Shire files New Drug Application for adult ADHD treatment
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
7/18/2006 | BT | Shire says Fosrenol shows effective phosphate control
|
6/29/2006 | BT | Shire's Daytrana patch for treatment of ADHD symptoms available in retail pharmacies
|
6/19/2006 | BT | New River: Studies show NRP104 less euphoric than other ADHD drugs
|
5/25/2006 | BT | Shire's attention-deficit drug Daytrana shows shorter wear time
|
5/25/2006 | BT | Market Commentary: Cubist explodes ahead of Cubicin vote; Encysive advances; Seattle Genetics, Progenics gain on pact
|
5/24/2006 | BT | Shire's Daytrana transdermal system for ADHD well tolerated in clinical trials
|
5/24/2006 | BT | Shire's MMX mesalamine induced remission in patients with ulcerative colitis
|
5/24/2006 | BT | Shire, New River present positive study results for ADHD drug NRP104
|
5/18/2006 | BT | Shire files suit Corepharma for infringing Carbatrol patents
|
5/17/2006 | BT | Shire says FDA extends review of marketing application for Elaprase by 90 days
|
4/21/2006 | BT | Shire says Fosrenol reduces tablet burden, improves satisfaction for renal disease patients
|
4/20/2006 | BT | FDA responds to Shire's Citizen Petition for Adderall XR
|
4/6/2006 | BT | Shire receives paragraph IV notice letter from Corepharma
|
4/6/2006 | BT | Shire's Daytrana patch gets FDA approval for ADHD treatment
|
3/10/2006 | BT | Shire says FDA confirms resubmission of Daytrana application
|
3/3/2006 | BT | Shire sues Teva for patent infringement after Teva files for approval of generic Adderall
|
3/1/2006 | BT | Shire on hold by Jefferies
|
2/10/2006 | BT | Shire at hold by Jefferies
|
12/23/2005 | BT | Shire, Noven receives FDA approvable letter for Daytrana ADHD drug
|
12/22/2005 | BT | Shire submits NDA for Mesavance to treat ulcerative colitis
|
12/7/2005 | BT | New River, Shire announce New Drug Application for ADHD-drug NRP104
|
12/2/2005 | BT | Shire, Noven says FDA advisory committee gave Daytrana patch for ADHD a thumb's up
|
12/1/2005 | BT | Shire submits marketing application for Hunter Syndrome in Europe
|
11/28/2005 | BT | Shire submits Biologics License Application to FDA for Elaprase
|
11/28/2005 | BT | Shire completes corporate restructuring
|